Compounds and uses thereof for the modulation of hemoglobin
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
1. A compound of Formula (I′)
or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein
ring A is a 5 or 6 membered heteroaryl containing up to 3 ring heteroatoms, wherein each heteroatom is independently selected from the group consisting of N, O, S, and oxidized forms of N and S, and wherein the heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of halo, OH, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy, wherein the C 1 -C 6 alkyl is optionally substituted with 1-5 halo;
wherein ring A is α or β substituted relative to the Y substituent;
ring B is phenyl or a 5 or 6 membered heterocycle containing 1 or 2 ring heteroatoms, wherein each heteroatom is independently selected from the group consisting of O, N, S, and oxidized forms of N and S, and wherein the phenyl or heterocycle is optionally substituted with one substituent selected from the group consisting of oxo, halo, OH, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, COR 15 , and COOR 15 ; wherein R 15 is C 1 -C 6 alkyl;
Y—Z is selected from the group consisting of —CH 2 O—, —CH 2 CH 2 —, —CONH— and —NHCO—, wherein the left side is joined with ring B;
R 5 is hydrogen or C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is optionally substituted with 1-5 halo;
each R 6 is independently selected from the group consisting of halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and C 1 -C 6 alkylthio, wherein the C 1 -C 6 alkyl is optionally substituted with 1-5 halo; and
p is 0, 1, 2, or 3.
2. The compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein p is 0.
3. The compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein ring A is optionally substituted with one substituent selected from the group consisting of C 1 -C 6 alkyl and C 1 -C 6 alkoxy.
4. The compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein ring B is optionally substituted with one substituent selected from the group consisting of halo, C 1 -C 6 alkyl, COR 15 , and COOR 15 .
5. The compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein Y—Z is —CH 2 O—, —CH 2 CH 2 —, or —CONH—.
6. A compound selected from the group consisting of:
or an N oxide thereof, or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.
7. A pharmaceutical composition comprising a compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, and at least one pharmaceutically acceptable excipient.
8. A method for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.
9. A pharmaceutical composition comprising a compound of claim 6 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, and at least one pharmaceutically acceptable excipient.
10. A method for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 6 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.
11. A compound selected from the group consisting of
or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof,
wherein
Y—Z is —CH 2 O—, —CH 2 CH 2 —, —CONH— or —NHCO—, wherein the right hand side is joined with the substituted phenyl ring;
x is 0, 1, or 2;
R 14 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, COR 15 , or COOR 15 ; and
R 15 is C 1 -C 6 alkyl.
12. The compound of claim 11 selected from the group consisting of
or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.
13. A pharmaceutical composition comprising a compound of claim 11 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, and at least one pharmaceutically acceptable excipient.
14. A method for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 11 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.
15. A compound of Formula (I′):
or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein
ring A is a heteroaryl selected from the group consisting of furanyl, imidazolyl, oxadiazolyl, oxazolyl, pyrazolyl and pyridinyl, wherein the heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of halo, OH, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy, wherein the C 1 -C 6 alkyl is optionally substituted with 1-5 halo;
wherein ring A is α or β substituted relative to the Y substituent;
ring B is phenyl or a heterocycle selected from the group consisting of oxazolinyl, piperidinyl, piperazinyl, pyrrolidinyl, dihydropyrrolyl, morpholino, tetrahydropyridinyl, dihydrofuranyl, tetrahydrofuranyl, dihydropyranyl, and tetrahydropyranyl, wherein the phenyl or heterocycle is optionally substituted with a substituent selected from the group consisting of oxo, halo, OH, C 1 -C 6 alkyl, COR 15 , and COOR 15 ; wherein R 15 is C 1 -C 6 alkyl;
Y—Z is —CH 2 O—, —CH 2 CH 2 —, —CONH— or —NHCO—, wherein the left hand side is joined with ring B;
R 5 is hydrogen or C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is optionally substituted with 1-5 halo;
each R 6 is independently selected from the group consisting of halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and C 1 -C 6 alkylthio, wherein the C 1 -C 6 alkyl is optionally substituted with 1-5 halo; and
p is 0, 1, 2, or 3.
16. The compound of claim 15 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein p is 0.
17. The compound of claim 15 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein ring A is pyrazolyl or pyridinyl, and the pyrazolyl or pyridinyl is optionally substituted with a C 1 -C 6 alkyl or C 1 -C 6 alkoxy.
18. The compound of claim 15 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein ring B is phenyl optionally substituted with one substituent selected from the group consisting of halo, OH, C 1 -C 6 alkyl, COR 15 , and COOR 15 .
19. The compound of claim 15 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein ring B is a heterocycle selected from the group consisting of piperidinyl, pyrrolidinyl, dihydropyrrolyl, morpholino, tetrahydropyridinyl, dihydrofuranyl, tetrahydrofuranyl, dihydropyranyl, and tetrahydropyranyl, wherein the heterocycle is optionally substituted with one substituent selected from the group consisting of oxo and methyl.
20. A pharmaceutical composition comprising a compound of claim 15 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, and at least one pharmaceutically acceptable excipient.
21. A method for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 15 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.